In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear attacks. In this report Dr. Robert Kadlec writes that Project BioShield has achieved its strategic objectives and merits continued support and funding. He argues that the president and Congress should affirm its value as a critical insurance policy against the risk of these types of attacks
Notes
"January 2013."
Bibliography
Includes bibliographical references (pages 13-16)
Notes
Online resource; title from PDF page 1 (CNAS, viewed October 10, 2013)